Applicable Symptoms: It is a soluble and phlegm-free drug for viscosity, and is suitable for acute and chronic rhinosinusitis as well as respiratory diseases such as acute and chronic bronchitis, pneumonia, bronchial dilation, pulmonary abscess, chronic obstructive pulmonary disease, bacterial infection in the lungs, tuberculosis, and silica lungs. It can also be used for bronchoscopic angiography to facilitate the discharge of contrast medium. It is a China exclusive product independently developed by the Group with two separate types of drugs for adult and children’s use and was included in China’s National Reimbursement Drug List in 2017 and China’s National Essential Drug List in 2018 respectively, and was listed in the Top Brands of the Health Industry in 2022 (二零二二年健康產業品牌銳榜). Currently, there are dozens of guidelines and expert consensus recommending the use of viscosity dissolving promotors for clinical use. Among them, about a dozen guidelines and expert consensus explicitly recommend eucalyptol, limonene and pinene enteric soft capsules or its active ingredients for clinical treatment, such as the Expert Consensus on the Diagnosis and Treatment of Adult Bronchiectasis in China (《中國成人支氣管擴張症診斷與治療專家共識》), the Guidelines for the Diagnosis and Treatment of Secretory Otitis Media in Children (2021) (《兒童分泌性中耳炎診 斷和治療指南（2021）》), the Diagnosis and Treatment Guidelines for Cough (2021) (《咳嗽的診 斷與治療指南(2021)》), the Guidelines for Rational Use of Drugs for Chronic COPD in Primary Care (2020) (《慢性阻塞性肺疾病基層合理用藥指南 (2020)》), the Chinese Expert Consensus - Chinese (2015) on High-secretion Management of Gastrointestinal Adhesis for Chronic Gastropic Diseases (《慢性氣道炎症性疾病氣道黏液高分泌管理中國專家共識 - 中文版 (2015)》), etc. Its clinical status is prominent, and the level of recognition among doctors and patients is high, continuing to lead the market of oral cough relieving and phlegm relieving drugs.